Ifinatamab deruxtecan - Daiichi Sankyo Company
Alternative Names: DS-7300; DS-7300a; I-DXd; MK-2400Latest Information Update: 08 Jul 2025
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Merck & Co
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Prostate cancer; Small cell lung cancer; Squamous cell cancer
- Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Phase I/II Solid tumours
Most Recent Events
- 25 Jun 2025 Merck Sharp & Dohme initiates a phase I/II IDeate-Prostate02 trial for Prostate cancer (Hormone refractory, Metastatic disease, Second line therapy or greater) (IV, Infusion) (NCT06863272) (EudraCT2024-516036-94)
- 19 May 2025 Ifinatamab deruxtecan - Daiichi Sankyo Company receives Orphan Drug status for Small cell lung cancer in Japan
- 19 May 2025 Ifinatamab deruxtecan - Daiichi Sankyo Company receives Orphan Drug status for Small cell lung cancer in Taiwan